145 related articles for article (PubMed ID: 25789004)
1. Imaging features of glucagonoma syndrome: A case report and review of the literature.
Lv WF; Han JK; Liu X; Wang SC; Pan BO; Xu AO
Oncol Lett; 2015 Apr; 9(4):1579-1582. PubMed ID: 25789004
[TBL] [Abstract][Full Text] [Related]
2. Malignant glucagonoma of the pancreas diagnoses through anemia and diabetes mellitus.
Koike N; Hatori T; Imaizumi T; Harada N; Fukuda A; Takasaki K; Iwamoto Y
J Hepatobiliary Pancreat Surg; 2003; 10(1):101-5. PubMed ID: 12918465
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Imaging features of primary hepatic leiomyosarcoma: A case report and review of literature.
Lv WF; Han JK; Cheng DL; Tang WJ; Lu D
Oncol Lett; 2015 May; 9(5):2256-2260. PubMed ID: 26137052
[TBL] [Abstract][Full Text] [Related]
5. Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.
Cao X; Wang X; Lu Y; Zhao B; Shi J; Guan Q; Zhang X
Medicine (Baltimore); 2019 Sep; 98(38):e17037. PubMed ID: 31567941
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of a glucagonoma with
Fathala A; Al Qahtani MH; Abouzied MM
Radiol Case Rep; 2020 Jan; 15(1):19-22. PubMed ID: 31737140
[TBL] [Abstract][Full Text] [Related]
7. Benign-Appearing Glucagonoma Undergoing Malignant Transformation after a Prolonged Period.
Shakir MKM; Ebrahim IC; Snitchler AN; Mai VQ; Hoang TD
Case Rep Oncol; 2020; 13(3):1109-1115. PubMed ID: 33082756
[TBL] [Abstract][Full Text] [Related]
8. Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy.
Barabas M; Huang-Doran I; Pitfield D; Philips H; Goonewardene M; Casey RT; Challis BG
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836327
[TBL] [Abstract][Full Text] [Related]
9. Glucagonoma syndrome associated with necrolytic migratory erythema.
Cardoso Filho Fde A; Feitosa RG; Fechine CO; Matos CM; Cardoso AL; Cardoso DL
Rev Assoc Med Bras (1992); 2015; 61(3):203-6. PubMed ID: 26248239
[TBL] [Abstract][Full Text] [Related]
10. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT.
Seith F; Schraml C; Reischl G; Nikolaou K; Pfannenberg C; la Fougère C; Schwenzer N
Radiol Med; 2018 Nov; 123(11):860-870. PubMed ID: 29961229
[TBL] [Abstract][Full Text] [Related]
11. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
12. Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.
Kawsar HI; Habib A; Saeed A; Saeed A
J Community Hosp Intern Med Perspect; 2019; 9(5):425-429. PubMed ID: 31723389
[TBL] [Abstract][Full Text] [Related]
13. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
[TBL] [Abstract][Full Text] [Related]
14. Diversity of imaging features of ovarian sclerosing stromal tumors on MRI and PET-CT: a case report and literature review.
Matsutani H; Nakai G; Yamada T; Yamamoto K; Ohmichi M; Narumi Y
J Ovarian Res; 2018 Dec; 11(1):101. PubMed ID: 30572921
[TBL] [Abstract][Full Text] [Related]
15. Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol.
Peerlings J; Paulis L; Mitea C; Bakers F; Berbée M; Wierts R; Vöö S; Wildberger J; Hoffmann A; Lambin P; Mottaghy F
Nucl Med Commun; 2019 Aug; 40(8):815-826. PubMed ID: 31169592
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
Seemann MD; Meisetschlaeger G; Gaa J; Rummeny EJ
Eur J Med Res; 2006 Feb; 11(2):58-65. PubMed ID: 16504962
[TBL] [Abstract][Full Text] [Related]
17. Malignant glucagonoma. New options of treatment.
Appetecchia M; Ferretti E; Carducci M; Izzo F; Carpanese L; Marandino F; Terzoli E
J Exp Clin Cancer Res; 2006 Mar; 25(1):135-9. PubMed ID: 16761630
[TBL] [Abstract][Full Text] [Related]
18. Glucagonoma syndrome: report of one case.
Han X; Wang D; Kuang T; Rong Y; Lou W
Transl Gastroenterol Hepatol; 2016; 1():70. PubMed ID: 28138636
[TBL] [Abstract][Full Text] [Related]
19. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to
Zheng D; Liu Y; Liu J; Li K; Lin M; Schmidt H; Xu B; Tian J
Cancer Imaging; 2020 Jun; 20(1):39. PubMed ID: 32546207
[TBL] [Abstract][Full Text] [Related]
20. An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography.
Azemoto N; Kumagi T; Yokota T; Kuroda T; Koizumi M; Yamanishi H; Soga Y; Furukawa S; Abe M; Ikeda Y; Hiasa Y; Matsuura B; Watanabe J; Kushihata F; Onji M
Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):e43-7. PubMed ID: 22239827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
